Imprimed

ImpriMed is an AI-driven precision medicine company founded in 2017 by Stanford-trained engineers Sungwon Lim and Jamin Koo. The company combines quantitative high-throughput live-cell drug sensitivity testing with artificial intelligence to predict which anticancer drugs will be most effective for individual cancer patients. ImpriMed's platform first launched in the veterinary oncology market, where it has helped over 250 veterinary oncologists across 40 U.S. states deliver personalized treatments to dogs with lymphoma and leukemia. The platform uses an ex vivo drug sensitivity assay that measures how a patient's live tumor cells respond to a panel of anticancer drugs, then applies AI models trained on ImpriMed's proprietary real-world clinical outcomes database to generate a comprehensive personalized drug prediction profile. Building on its veterinary success, ImpriMed has expanded into human oncology and offers pharma CRO services to accelerate oncology drug development pipelines. The company is headquartered in Palo Alto, California, with an additional office in Seoul, South Korea.